Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: Have we answered the question?

Clinical and Translational Oncology

Volumn 12, Issue 9, 2010, Pages 614-620

  Sánchez Muñz, Alfonso ^a   Ribelles, Nuria ^a   Alba, Emilio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Aromatase inhibitors; Breast cancer; Survival; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; HORMONE RECEPTOR; LETROZOLE; PLACEBO; TAMOXIFEN;

ADJUVANT THERAPY; ARTHRALGIA; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FRACTURE; HUMAN; MONOTHERAPY; MYALGIA; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN;

EID: 77958174467     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0566-9     Document Type: Review

References (36)

1. D.M. Parkin F. Bray J. Ferlay P. Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108 10.3322/canjclin.55.2.74 15761078 (Pubitemid 40372904)
2. C.I. Li J.R. Daling K.E. Malone 2003 Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998 J Clin Oncol 21 28 34 1:CAS:528:DC%2BD38XpvVWntrg%3D 10.1200/JCO.2003.03.088 12506166
3. Early Breast Cancer Trialists' Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
4. L.C. Dorssers S. Van der Flier A. Brinkman, et al. 2001 Tamoxifen resistance in breast cancer: elucidating mechanisms Drugs 61 12 1721 33 1:CAS:528:DC%2BD3MXot1Cntrs%3D 10.2165/00003495-200161120-00004 11693462 (Pubitemid 32980504)
5. A. Brodie D. Jelovac B.J. Long 2003 Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens Clin Cancer Res 9 455S 459S 1:CAS:528:DC%2BD3sXnt1yjsA%3D%3D 12538500 (Pubitemid 36105787)
6. J.F. Forbes J. Cuzick A. Buzdar, et al. 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 45 53 10.1016/S1470-2045(07)70385-6 18083636
7. H. Mouridsen A. Giobbie-Hurder A. Goldhirsch, et al. 2009 Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. BIG 1-98 Collaborative Group N Engl J Med 361 766 776 1:CAS:528:DC%2BD1MXhtVWls7fM 10.1056/NEJMoa0810818 19692688
8. Rea D, Hasenburg A, Seynaeve C, et al. Five Years of Exemestane as Initial Therapy Compared to 5 Years of Tamoxifen Followed by Exemestane: The TEAM Trial, a Prospective, Randomized, Phase III Trial in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer. Presented at SABCS 2009. Abstract 11.
9. R. Coombes L. Kilburn S. Beare C. Snowdon J. Bliss 2009 Survival and safety post study treatment completion: an updated analysis of the Intergroup Exemestane Study (IES) - submitted on behalf of the IES Investigators Eur J Cancer Supplements 2 263 10.1016/S1359-6349(09)70902-4
10. R. Jakesz W. Jonat M. Gnant, et al. 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 455 462 1:CAS:528:DC%2BD2MXntVeisLw%3D 10.1016/S0140-6736(05)67059-6 16084253 (Pubitemid 41111693)
11. F. Boccardo A. Rubagotti P. Guglielmini, et al. 2006 Switching to anastrozole vs continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial Ann Oncol 17 vii10 vii14 10.1093/annonc/mdl941 16760270 (Pubitemid 43985170)
12. A.H. Brodie D. Jelovac B. Long 2003 The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens J Steroid Biochem Mol Biol 86 283 288 1:CAS:528:DC%2BD3sXptVemsrk%3D 10.1016/S0960-0760(03)00368-6 14623522 (Pubitemid 37412566)
13. H. Mouridsen M. Gershanovich Y. Sun, et al. 2003 Phase III study of letrozole vs tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 21 2101 2109 1:CAS:528:DC%2BD2cXpsVGqtLY%3D 10.1200/JCO.2003.04.194 12775735 (Pubitemid 46606358)
14. J. Mansell I.J. Monypenny A.I. Skene, et al. 2009 Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer Breast Cancer Res Treat 117 91 8 1:CAS:528: DC%2BD1MXpvFyitbg%3D 10.1007/s10549-008-0291-z 19112615
15. J. Houghton 2006 Initial adjuvant therapy with anastrozole reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen - data reported on behalf of the ATAC (Arimidex, tamoxifen, alone or in Combination) Trialists' group Ann Oncol. 17 Suppl.9 ix94
16. L. Mauriac A. Keshaviah M. Debled BIG 1-98 Collaborative Group; International Breast Cancer Study Group, et al. 2007 Predictors of early relapse in postmenopausal women with hormone receptorpositive breast cancer in the BIG 1-98 trial Ann Oncol. 18 859 867 1:STN:280:DC%2BD2s3ns1Kksg%3D%3D 10.1093/annonc/mdm001 17301074 (Pubitemid 47054082)
17. M.G. Lê R. Arriagada M. Spielmann, et al. 2002 Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma Cancer 94 2813 2820 10.1002/cncr.10572 12115367 (Pubitemid 34547678)
18. C.A. Hudis W.E. Barlow J.P. Costantino, et al. 2007 Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system J Clin Oncol 25 2127 2132 10.1200/JCO.2006.10.3523 17513820 (Pubitemid 46972801)
19. A. Howell J. Cuzick M. Baum ATAC Trialists' Group, et al. 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 60 62 1:STN:280:DC%2BD2M%2FhsVartA%3D%3D 10.1016/S0140-6736(05)74803-0 15639680 (Pubitemid 40082147)
20. Breast International Group B. Thürlimann A. Keshaviah A.S. Coates H. Mouridsen L. Mauriac J.F. Forbes R. Paridaens M. Castiglione-Gertsch R.D. Gelber M. Rabaglio I. Smith A. Wardley K.N. Price A. Goldhirsch 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med. 353 2747 57 10.1056/NEJMoa052258 16382061 (Pubitemid 43016814)
21. B. Fisher J. Costantino C. Redmond, et al. 1989 A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors N Engl J Med 320 479 484 1:STN:280:DyaL1M7islChsw%3D%3D 10.1056/NEJM198902233200802 2644532 (Pubitemid 19062522)
22. L.E. Rutqvist H. Johansson Stockholm Breast Cancer Study Group 2007 Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer Acta Oncol 46 133 145 1:CAS:528:DC%2BD2sXjs1GlsL0%3D 10.1080/02841860601034834 17453361 (Pubitemid 46277056)
23. Regan MM, Colleoni M, Giobbie-Hurder A, et al. Adjusting for Selective Crossover in Analyses of Letrozole (Let) Versus Tamoxifen (Tam) in the BIG 1-98 Trial. Presented at: San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, TX [abstract 16].
24. Jones SE, Seynaeve C, Hasenburg A, et al: Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Cancer Res 69(Suppl 2): Abstract no 15, 2009.
25. R.C. Coombes E. Hall L.J. Gibson, et al. 2004 Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med. 350 1081 1092 1:CAS:528:DC%2BD2cXitV2qtbc%3D 10.1056/NEJMoa040331 15014181 (Pubitemid 38298988)
26. R.C. Coombes L.S. Kilburn C.F. Snowdon Intergroup Exemestane Study, et al. 2007 Survival and safety of exemestane vs tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet 369 559 570 1:CAS:528:DC%2BD2sXhvVGgsro%3D 10.1016/S0140-6736(07)60200-1 17307102 (Pubitemid 46251559)
27. R. Jakesz M. Gnant R. Greil, et al. 2005 The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8 Breast Cancer Res Treat 94 Suppl1 S10 (Pubitemid 41111693)
28. M. Dowsett C. Allred J. Knox, et al. 2008 Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER2) status with recurrence in the Arimidex, Tamoxifen, alone or in combination trial J Clin Oncol 26 1059 1065 1:CAS:528:DC%2BD1cXktVKisbg%3D 10.1200/JCO.2007.12.9437 18227529
29. B.B. Rasmussen M.M. Regan A.E. Lykkesfeldt, et al. 2008 Adjuvant letrozole vs tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomized trial Lancet Oncol 9 23 28 1:CAS:528:DC%2BD1cXivVOmuw%3D%3D 10.1016/S1470-2045(07)70386-8 18083065
30. W.J. Gradishar 2005 Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women Oncology 69 1 9 10.1159/000087282 16088229 (Pubitemid 41207052)
31. P. Conte A. Frassoldati 2007 Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective Breast J 13 28 35 1:CAS:528:DC%2BD2sXitVemsLo%3D 10.1111/j.1524-4741.2006.00359.x 17214790 (Pubitemid 46046490)
32. E.A. Perez 2007 Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer Ann Oncol 18 Suppl8 viii26 35 10.1093/annonc/mdm263 17890211
33. Thürlimann B; for the BIG 1-98 Collaborative & International Breast Cancer Study Groups. Letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer: update of the BIG 1-98 Primary Core Analysis (PCA). Primary Therapy of Early Breast Cancer 2009, 11th International Conference, March 11-14, St. Gallen, Switzerland [abstract 0161].
34. L. Fallowfield 2007 Quality of life issues in relation to the aromatase inhibitor J Steroid Biochem Mol Biol 106 168 172 1:CAS:528:DC%2BD2sXhtVWitbvF 10.1016/j.jsbmb.2007.05.003 17587567 (Pubitemid 47362651)
35. G. Viale A. Giobbie-Hurder M.M. Regan Breast International Group Trial 1-98, et al. 2008 Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole J Clin Oncol 26 5569 5575 10.1200/JCO.2008.17.0829 18981464
36. Arimidex, Tamoxifen, Alone or in Combination Trialists' Group A. Buzdar A. Howell J. Cuzick, et al. 2006 Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial Lancet Oncol. 7 633 643 1:STN:280:DC%2BD28vmsVOmsQ%3D%3D 10.1016/S1470-2045(06)70767-7 16887480 (Pubitemid 44123570)